Results for 'Life Reset Labs'
Michael Pietrack
Leading From the Front: 3 Leadership Lessons From Mark Cuban
Dec 17th • 6 mins read
Michael Pietrack
Leadership Lab: Take a Cue From Athletes by Working With an Executive Coach
Feb 19th • 6 mins read
Michael Pietrack
Leadership Lab: How To Spot When Employees Are About To Walk Away
Oct 22nd • 7 mins read
Michael Pietrack
Leadership Lab: 4 Ways Biopharma Leaders Can Prepare for Media Interviews
Aug 20th • 6 mins read
Michael Pietrack
The Four Employment Agreement Questions Every Pharma Executive Must Ask
Dec 18th • 6 mins read
Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
Sep 9th • 5 mins read
Tom Caravela
Combatting the “Summer Slow Down" – MSL Job Search Tips for Slower Months
Jun 23rd • 2 mins read
iNIZIO
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Feb 22nd • 10 mins read
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Feb 11th • 4 mins read
Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons
Sep 14th • 4 mins read
Paulo J. Oliveira, Ana M. Urbano
“Oncometabolism: The switchboard of cancer: An editorial”
Feb 1st • 1 min read
Daan Geert Knapen, Nathan I. Cherny, Panagiota Zygoura, Nicola Jane Latino, Jean-Yves Douillard, Urania Dafni, Elisabeth G.E. de Vries, Derk Jan de Groot
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Sep 6th • 17 mins read
Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Aug 31st • 16 mins read